Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
REGULATORY
MHLW Seeks 20.6 Billion Yen for MCM Stockpiles, Revenue Guarantees
The Ministry of Health, Labor and Welfare (MHLW) is seeking 20.6 billion yen in its FY2027 budget request to secure medical countermeasures (MCMs) through government purchases, stockpiling, and revenue guarantees for drug makers. MCMs are critical during infectious disease outbreaks…
To read the full story
Related Article
- Japan Eyes Multi-Year Funding to Secure MCMs: Takaichi
October 14, 2026
- MHLW Seeks at Least 275 Billion Yen to Shore Up Drug Supplies
September 7, 2026
- MHLW Tax Reform Requests Cover Support for MCM Preparedness
August 28, 2026
- MHLW Seeks Record 36.6 Trillion Yen for FY2027, Puts AI in Focus
August 27, 2026
REGULATORY
- Panel Backs RSV Antibodies for Japan’s Routine Immunization Program
October 23, 2026
- Japan Weighs Possible Approval Revocation for Tavneos, Action Against Kissei
October 22, 2026
- Hernexeos, Rinvoq, Tukysa Label Expansions Now in Line for Japan Approval
October 22, 2026
- LDP, Ishin Resume Social Security Talks, Chuikyo Reform to Follow
October 22, 2026
- LDP Health Chief Demands CEA Overhaul, Backs Freeze on Price Cuts
October 20, 2026
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…